NewsStocksSummit Therapeutics (SMMT) Stock Falls 17% Premarket After FDA Rejects Lung Cancer Drug Application

Summit Therapeutics (SMMT) Stock Falls 17% Premarket After FDA Rejects Lung Cancer Drug Application

Author: Coincentral·

Key Takeaways

  • •The FDA issued a Complete Response Letter on Sunday stating that ivonescimab, combined with platinum chemotherapy for previously treated EGFR-mutated non-small cell lung cancer, cannot be approved in its currently submitted form.
  • •The agency cited insufficient evidence of effectiveness, saying progression-free survival gains alone were inadequate and a statistically significant overall survival improvement was required, even though the HARMONi trial met its progression-free survival goal.
  • •Summit's stock dropped about 17% in premarket trading Monday to around $11.70, a new 52-week low after reaching as high as $29.23 during the past year.
  • •Jefferies viewed the rejection as the investor base case with limited downside and is watching HARMONi-3 squamous progression-free survival data due around the end of 2026, while Barclays kept an Equalweight rating and lowered its price target to $18 from $20.
  • •No regulator in Summit's license territories, including the United States and Europe, has approved ivonescimab, though China approved it in May 2024, and Summit said its commitment to the drug is unchanged, citing five positive Phase III studies conducted with partner Akeso.
Summit Therapeutics (SMMT) Stock Falls 17% Premarket After FDA Rejects Lung Cancer Drug Application

Summit Therapeutics (SMMT) fell roughly 17% in premarket trading on Monday, with the shares landing near $11.70 and marking a new 52-week low. The move followed the U.S. Food and Drug Administration's decision to reject the company's drug application for ivonescimab, leaving the investigational lung cancer therapy unapproved in its current form.

The setback came on Sunday, when the FDA issued a Complete Response Letter on the application, stating that ivonescimab cannot be approved as currently submitted. A Complete Response Letter is the regulator's mechanism for declining an application in its present form and typically lays out what additional evidence a sponsor would need before seeking approval again. The filing covered ivonescimab in combination with platinum-containing chemotherapy for locally advanced or metastatic non-small cell lung cancer in patients previously treated with an EGFR tyrosine kinase inhibitor, a class of targeted therapies for lung cancers driven by EGFR mutations.

The stock had climbed as high as $29.23 over the past year. It now sits close to the bottom of that range, trading around $12.07.

What the FDA Said

The agency determined that Summit had not demonstrated substantial evidence of effectiveness. The missing element, according to the FDA, was a statistically significant improvement in overall survival — a measure of whether patients actually live longer. The regulator said progression-free survival gains alone were not enough, and that survival data was needed to substantiate the benefit-risk case. Progression-free survival tracks how long a treatment keeps the disease from worsening, an endpoint that does not always translate into longer life.

The Phase 3 HARMONi trial did meet its progression-free survival goal. The overall survival result, however, fell short of statistical significance. Summit countered that the combination still showed a positive overall survival trend, and pointed out that no approved regimen in this treatment setting has demonstrated a statistically significant survival benefit.

A later analysis with longer follow-up of Western patients produced a hazard ratio of 0.76 — a statistical measure in which a value below 1 indicates a lower risk of death during the study period. That figure held across the full study group, as well as among Asian patients and Western patients. The safety profile was described as manageable, with no new safety signals identified and discontinuation and death rates similar across both trial arms.

Analyst and Partner Reactions

Jefferies described the rejection as the base case for investors and sees limited downside, arguing that second-line EGFR was never central to the investment story. The firm also noted that Summit had earlier shared that it was not aligned with the FDA on this filing. Jefferies is now watching for HARMONi-3 squamous progression-free survival data, expected around the end of 2026.

Barclays maintained its Equalweight rating on the stock while trimming its price target to $18 from $20.

Akeso, Summit's partner, issued a notice on Monday regarding abnormal swings in its stock price. The notice came after Summit's press release on Sunday.

The broader market offered no cushion. The Nasdaq closed down 0.91% on Friday, and weakness in technology stocks carried into the new week.

Regulatory Status

No regulator in Summit's license territories, including the United States and Europe, has approved ivonescimab. China approved the drug in May 2024, a reminder that each regulator weighs the evidence on its own terms and that approval in one market does not carry over to another.

Summit said its commitment to ivonescimab is unchanged, citing five positive Phase III studies conducted across Summit and Akeso.

Source: CoinCentral